Selecting the right molecule for the UK market is no longer a simple exercise of tracking patent expiries. It requires a structured, data-driven approach that integrates clinical need, regulatory feasibility, technical capability, and commercial attractiveness.
Based on practical experience in generic and value-added product development, the following framework can support business development and R&D teams in making informed decisions.
1. Start with Real Market Need
Begin with demand rather than molecules. Analyse NHS prescribing trends, high-spend therapy areas, and medicines facing supply shortages. Therapeutic areas such as cardiometabolic disorders, CNS, respiratory, and specialty hospital products continue to present strong opportunities.
2. Map the Patent and Exclusivity Landscape
Assess basic patents, secondary patents, supplementary protection certificates, and data exclusivity timelines. Molecules entering the 0–3 year pre-expiry window are typically optimal for pipeline planning.
3. Evaluate Competitive Intensity
Opportunities are strongest where competition is limited and supply reliability is critical. Products with fewer generic players or higher manufacturing complexity tend to maintain more sustainable margins.
4. Assess Technical Feasibility
Technical capability is a key differentiator. Complex formulations, difficult APIs, modified-release systems, injectables, and patient-centric adaptations such as liquid formulations for dysphagia can create meaningful barriers to entry.
5. Define the Regulatory Pathway
Clarify whether the product will follow a generic, hybrid, or well-established use pathway under MHRA. Early understanding of bioequivalence strategy and CMC requirements helps reduce development risk.
6. Validate Commercial Attractiveness
A structured scoring model incorporating market size, development cost, time to market, and margin potential allows objective prioritisation of opportunities.
Key Insight
Successful molecule selection in the UK requires cross-functional alignment between business development, regulatory, and R&D, supported by robust market intelligence. Organisations that adopt a structured selection framework significantly improve portfolio success rates and accelerate time to market.
Read also: Types of Variation Filings in UK and Europe